Achieving the best outcome in treatment of depression

Journal of Family Practice, March, 2003 by John E. Sutherland, Steven J. Sutherland, James D. Hoehns

(37.) Product information. Serzone(c) (nefazodone). Princeton, NJ: Bristol Myers Squibb Co., 2002 (January).

(38.) Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002: 59:233-239.

(39.) Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ. A proposed algorithm for improved recognition and treatment of depression/anxiety spectrum in primary care. J Clin Psychiatry 2001; 3:44-52.

(40.) Thase ME, Feighner JP, Lydiard RB. Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry 2001; 62:683-687.

(41.) Nelson JC, Mazure CM, Bowers MB, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48:303-307.

(42.) Stein G, Bernardt M. Lithium augmentation therapy in tricyclic resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993;162:634-640.

(43.) Joffe RT, Singer W. Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyrodine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393.

(44.) Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19:427-434.

(45.) Harvey KV, Balon R. Augmentation with buspirone: a review. Ann Clin Psychiatry 1995; 2;143-147.

(46.) Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Karen Press; 1995:1081-1097.

(47.) Prange AJ Jr., Loosen PT, Wilson IC, Lipton MA. The therapeutic use of hormone of the thyroid axis in depression. In: Post R, Ballenger J. Neurobiology of mood disorders. Vol 1. Baltimore, Md: Williams & Wilkins; 1980:311-322.

(48.) Gagne GG, Furman MJ, Carpenter LL, Price LH. Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psychiatry 2000; 157:1960-1965.

(49.) American Psychiatric Association. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. Washington, DC: American Psychiatric Association, 1990.

(50.) Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131-134.

(51.) Trivedi MH, Kleiber BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry 2001; 62(suppl 6):22-29.

(52.) Montana CB. Recognition and treatment of depression in a primary care setting. J Clin Psychiatry 1994; 55(suppl 1):18-34.

RELATED ARTICLE: The burden of depression.

At any one time, at least 3% of the US population suffers from chronic depression. (2) More than 17% of the population have had a major depressive episode in their lifetime, and more than 10% have experienced an episode within the past 12 months. (3) The incidence and prevalence of depression in women are approximately twice that seen in men. (4)